Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients

Lars Sondergaard

doi:10.1016/j.jcin.2016.08.015

Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients

Lars Sondergaard^*

^*Corresponding author for this work

Department of Clinical Medicine

17 Citations (Scopus)

Abstract

During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles’ heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.

Original language	English
Journal	J A C C: Cardiovascular Interventions
Volume	9
Issue number	21
Pages (from-to)	2183-2185
Number of pages	3
ISSN	1936-8798
DOIs	https://doi.org/10.1016/j.jcin.2016.08.015
Publication status	Published - 14 Nov 2016

Keywords

aortic stenosis
risk
SAVR
TAVR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcin.2016.08.015

Cite this

@article{f09abacfec64412daf18900c47f50e03,

title = "Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients",

abstract = "During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles{\textquoteright} heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.",

keywords = "aortic stenosis, risk, SAVR, TAVR",

author = "Lars Sondergaard",

year = "2016",

month = nov,

day = "14",

doi = "10.1016/j.jcin.2016.08.015",

language = "English",

volume = "9",

pages = "2183--2185",

journal = "J A C C: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier",

number = "21",

}

TY - JOUR

T1 - Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients

AU - Sondergaard, Lars

PY - 2016/11/14

Y1 - 2016/11/14

N2 - During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles’ heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.

AB - During the last decade transcatheter aortic valve replacement (TAVR) has been established as a treatment for patients with severe aortic stenosis, who are at particularly high surgical risk. As compared with surgical aortic valve replacement (SAVR), TAVR has been associated with lower early risk of mortality, atrial fibrillation, acute kidney injury, and bleeding. Furthermore, device and periprocedural improvements have addressed most of the initial limitations for TAVR, including the Achilles’ heel, paravalvular leakage. Supported by this as well as preliminary data among lower-risk patients, TAVR is currently being evaluated in prospective randomized trials against SAVR in younger low-risk patients. Although durability of the TAVR device may be of concern in younger patients given their longer life expectancy, intermediate-term controlled data does not reveal any difference between TAVR and SAVR devices.

KW - aortic stenosis

KW - risk

KW - SAVR

KW - TAVR

U2 - 10.1016/j.jcin.2016.08.015

DO - 10.1016/j.jcin.2016.08.015

M3 - Review

C2 - 27744040

AN - SCOPUS:84994389301

SN - 1936-8798

VL - 9

SP - 2183

EP - 2185

JO - J A C C: Cardiovascular Interventions

JF - J A C C: Cardiovascular Interventions

IS - 21

ER -